OSCR
Oscar Health, Inc.
OSCR has the edge over RVTY overall, supported by stronger valuation and stronger fundamentals.
RVTY
Revvity, Inc.
RVTY has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RVTY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
RVTY's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over RVTY in the historical PE scenario, which offers more potential upside but is not a forecast.
RVTY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $40.50 | -74% |
| Forward | 27x | $157 | — |
| Fair | 37x | $84.05 | -46% |
| Expensive | 54x | $121 | -23% |
| Current | 70x | $157 | — |
Historical ranges are pointers, not guarantees.
RVTY's PE is in its expensive range at 70x. If earnings grow as analysts expect, today's price would be 27x next year's earnings, in its fair range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over RVTY on the outlook, with more favorable revenue expectations.
RVTY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect RVTY's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over RVTY on earnings, with more consistent year-over-year improvement.
RVTY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.81 | +158% |
| Q3 2026 | $2.25 | +14% |
| Q2 2026 | $2.09 | -11% |
| Q1 2026 | $2.08 | -11% |
| Q4 2025 | $2.07 | -5.9% |
| Q3 2025 | $1.98 | -6.6% |
| Q2 2025 | $2.35 | +64% |
| Q1 2025 | $2.34 | +86% |
| Q4 2024 | $2.20 | -60% |
RVTY's earnings per share have fallen from their peak: $2.25 over the past year, against $10.51 in mid-2021.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RVTY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
RVTY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $728.9M | +4.3% |
| Q2 2026 | $729.7M | +1.3% |
| Q1 2026 | $711.1M | +7% |
| Q4 2025 | $772.1M | +5.9% |
| Q3 2025 | $698.9M | +2.2% |
| Q2 2025 | $720.3M | +4.1% |
| Q1 2025 | $664.8M | +2.3% |
| Q4 2024 | $729.4M | +4.8% |
RVTY's revenue has grown year over year for nine quarters in a row: $729M last quarter, up 4.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +1.3 points |
| Q2 2026 | 12% | -0.4 points |
| Q1 2026 | 11% | -0.2 points |
| Q4 2025 | 14% | -1.8 points |
| Q3 2025 | 12% | -2.6 points |
| Q2 2025 | 13% | +0.2 points |
| Q1 2025 | 11% | +4.1 points |
| Q4 2024 | 16% | +5.2 points |
RVTY has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over RVTY on cash flow, with more consistent year-over-year improvement.
RVTY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $152.4M | +27% |
| Q2 2026 | $180.9M | +57% |
| Q1 2026 | $95.5M | -15% |
| Q4 2025 | $161.8M | +8% |
| Q3 2025 | $120M | -4.4% |
| Q2 2025 | $115.5M | -15% |
| Q1 2025 | $112.2M | -14% |
| Q4 2024 | $149.8M | -13% |
RVTY still generates free cash flow, though less than at its 2021 peak: $590M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RVTY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +197K shares |
| 1 year | -3.1% | -3.6M shares |
| 3 years | -10% | -12.4M shares |
| 5 years | -2.8% | -3.2M shares |
| Available history | +0.3% | +325K shares |
RVTY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $95,000 |
| Q2 2026 | $16M |
| Q1 2026 | $86.5M |
| Q4 2025 | $168.3M |
| Q3 2025 | $205M |
| Q2 2025 | $293.9M |
| Q1 2025 | $153.6M |
| Q4 2024 | $185.2M |
RVTY spent $271M buying back its own shares over the past year, down 68% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over RVTY on leverage, with a lower net debt burden relative to earnings.
RVTY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.6x | Moderate |
| Q2 2026 | 2.8x | Moderate |
| Q1 2026 | 3.0x | Elevated |
| Q4 2025 | 3.0x | Elevated |
| Q3 2025 | 3.0x | Moderate |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 2.6x | Moderate |
| Q4 2024 | 2.6x | Moderate |
RVTY's net debt is about 2.6 years of its operating earnings (EBITDA), down from 3.0 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RVTY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.3 | Overbought |
| Stochastic | 76.5 | Neutral |
RVTY's weekly RSI is 74 (overbought) and its Stochastic is 77 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over RVTY on valuation relative to its sector.
RVTY PE vs Healthcare Sector
| Metric | RVTY | Sector median | Relative |
|---|---|---|---|
| PE | 70x | 26x | 170% above |
| PE % | 91 | 29 | 62 pts above |
RVTY is trading at 70x earnings, a 170% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
RVTY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $154.7 | 1.5% above |
| 20 week MA | $134.0 | 17% above |
| 50 week MA | $112.2 | 40% above |
| 100 week MA | $105.9 | 48% above |
| 200 week MA | $110.0 | 43% above |
RVTY has climbed back above all five of its weekly moving averages, and it's now 43% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RVTY on returns for 2026, with the stronger performance.
RVTY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $97.1 | $139.7 | +44% |
| 2021 | $139.7 | $193.8 | +39% |
| 2022 | $193.8 | $140.6 | -27% |
| 2023 | $140.6 | $109.3 | -22% |
| 2024 | $109.3 | $112.0 | +2.5% |
| 2025 | $112.0 | $96.8 | -14% |
| 2026 YTD | $96.8 | $157.0 | +62% |
RVTY is up 62% so far in 2026, after finishing lower in three of the previous six years.